Largest biotech companies by total assets
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech companies ranked by total assets, at SAR 339.8B, ahead of Gilead Sciences (SAR 221.4B) and Biogen (SAR 110.4B). Figures as of 18 Nov 2026, 19:03 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenSAR 339.8B
- Median
- SAR 9.6B
- Combined market value
- SAR 3.14T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SAR 339.8B | SAR 902.4B | SAR 1,668.35 | 2.87% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | SAR 221.4B | SAR 785.1B | SAR 632.94 | 0.89% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | SAR 110.4B | SAR 139.2B | SAR 941.58 | 0.09% up | 49% up | ||
| 4 | BioNTechBNTX · Health Care | SAR 91.5B | SAR 77.9B | SAR 314.33 | 1.25% down | 16% down | ||
| 5 | ModernaMRNA · Health Care | SAR 46.3B | SAR 302.4B | SAR 747.44 | 3.64% down | 755% up | ||
| 6 | argenxARGX · Health Care | SAR 32.6B | SAR 223.2B | SAR 3,549.91 | 0.12% down | 4% up | ||
| 7 | QiagenQGEN · Health Care | SAR 23.6B | SAR 38.5B | SAR 186.29 | 0.17% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | SAR 17.4B | SAR 62.2B | SAR 614.19 | 1.31% down | 20% up | ||
| 9 | VaxcytePCVX · Health Care | SAR 11.3B | SAR 34.7B | SAR 219.25 | 1.60% down | 22% up | ||
| 10 | RepligenRGEN · Health Care | SAR 11.1B | SAR 41.1B | SAR 643.65 | 5.81% up | 5% up | ||
| 11 | ExelixisEXEL · Health Care | SAR 10.7B | SAR 63B | SAR 258.22 | 0.50% up | 63% up | ||
| 12 | Bio-TechneTECH · Health Care | SAR 9.7B | SAR 42.9B | SAR 273.02 | 0.21% up | 26% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | SAR 9.5B | SAR 41.1B | SAR 360.55 | 0.16% up | 37% up | ||
| 14 | Revolution MedicinesRVMD · Health Care | SAR 8.8B | SAR 130.1B | SAR 601.64 | 1.41% down | 131% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | SAR 8.5B | SAR 14.9B | SAR 154.09 | 2.32% up | 21% down | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | SAR 6.5B | SAR 39B | SAR 457.36 | 0.34% up | 87% up | ||
| 17 | Krystal BiotechKRYS · Health Care | SAR 5B | SAR 34.9B | SAR 1,177.81 | 5.18% up | 46% up | ||
| 18 | ImmunovantIMVT · Health Care | SAR 3.6B | SAR 25.9B | SAR 124.95 | 0.30% up | 43% up | ||
| 19 | CG OncologyCGON · Health Care | SAR 3B | SAR 26.7B | SAR 298.39 | 0.77% up | 85% up | ||
| 20 | Twist BioscienceTWST · Health Care | SAR 2.4B | SAR 30.1B | SAR 441.14 | 5.00% up | 340% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | SAR 1.9B | SAR 17.3B | SAR 107.02 | 0.14% up | 88% up | ||
| 22 | ImmunityBioIBRX · Health Care | SAR 1.9B | SAR 26.3B | SAR 24.77 | 5.48% up | 193% up | ||
| 23 | Scholar Rock HoldingSRRK · Health Care | SAR 1.5B | SAR 21.7B | SAR 177.97 | 5.25% up | 14% up | ||
| 24 | Kodiak SciencesKOD · Health Care | SAR 1.3B | SAR 23.7B | SAR 362.01 | 0.30% down | 396% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which biotech companies rank first by total assets?
Amgen (SAR 339.8B), Gilead Sciences (SAR 221.4B) and Biogen (SAR 110.4B) are the top three of the 24 biotech companies ranked by total assets as of 18 Nov 2026, 19:03 UTC.
How many biotech companies are in this ranking?
24 are ranked by total assets.
What are these biotech companies worth together?
The 24 biotech companies ranked by total assets have a combined market value of SAR 3.14T as of 18 Nov 2026, 19:03 UTC.
What does ranking by total assets measure?
Everything the company owns, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by total assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-assets
Underlying data: Yahoo Finance; SEC EDGAR.